Xenon Pharmaceuticals Inc. (XENE) - Dilution Analysis

10-Q filing | 87.3M shares outstanding

10-Q filing | 79.2M shares outstanding

10-Q filing | 79.0M shares outstanding

10-Q filing | 78.7M shares outstanding

10-K filing | 77.9M shares outstanding

10-Q filing | 77.9M shares outstanding

10-Q filing | 77.7M shares outstanding

10-Q filing | 77.6M shares outstanding

10-K filing | 75.4M shares outstanding

8-K filing: Xenon Pharmaceuticals Inc. announced an underwritten public offering of 8,461,542 common shares at $32.50 per share and pre-funded warrants to purchase 769,230 common shares at $32.4999 per warrant, with net proceeds expected to be approximately $281.6 million.

10-Q filing | 66.0M shares outstanding

10-Q filing | 65.9M shares outstanding

10-Q filing | 65.7M shares outstanding

10-K filing | 60.5M shares outstanding

10-Q filing | 65.5M shares outstanding

10-Q filing | 56.2M shares outstanding

8-K filing: Xenon Pharmaceuticals Inc. entered into an underwriting agreement for a public offering of 7,868,854 common shares and pre-funded warrants to purchase 327,868 common shares at an exercise price of $0.0001 per share, with the offering price of the common shares at $30.50 per share and the pre-funded warrants at $30.4999 per warrant. ($234.6M proceeds)

10-Q filing | 53.1M shares outstanding

10-K filing | 51.9M shares outstanding

8-K filing: Xenon Pharmaceuticals Inc. issued and sold 258,986 common shares to Neurocrine Biosciences, Inc. in a private placement for $8.25 million at a price of $31.855 per share. ($0.0M proceeds)

10-Q filing | 51.6M shares outstanding

8-K filing: Xenon Pharmaceuticals Inc. entered into an underwriting agreement for a public offering of 8,474,577 common shares and pre-funded warrants to purchase 1,694,915 common shares at an exercise price of $0.0001 per share, with the offering price of the Firm Shares at $29.50 per common share and the Pre-Funded Warrants at $29.4999 per Pre-Funded Warrant. ($300.0M proceeds)

8-K filing: Xenon Pharmaceuticals Inc. issued and sold 275,337 common shares to Neurocrine Biosciences, Inc. in a private placement for $5.5 million, or $19.9755 per share, pursuant to a Share Purchase Agreement. ($5.5M proceeds)

10-Q filing | 41.1M shares outstanding

10-Q filing | 41.0M shares outstanding

8-K filing: Xenon Pharmaceuticals Inc. entered into an underwriting agreement for a public offering of 4,324,325 common shares at $18.50 per share and pre-funded warrants to purchase 1,081,081 common shares at an exercise price of $0.0001 per share, with net proceeds expected to be approximately $93.7 million. ($80.02M proceeds)

10-K filing | 35.8M shares outstanding

10-Q filing | 35.0M shares outstanding

10-Q filing | 35.0M shares outstanding

S-3 filing: Xenon Pharmaceuticals Inc. is filing an S-3 to register Common Shares, Preferred Shares, Warrants and Units for a total proposed amount of $250,000,000.

10-K filing | 35.0M shares outstanding

8-K filing: Xenon Pharmaceuticals Inc. completed an at-the-market equity offering, selling 3,252,330 common shares for gross proceeds of $50.0 million and net proceeds of approximately $48.8 million. ($50.0M proceeds)